Your resource for the latest insights on the oncology and diagnostic landscape — from breaking innovations in advanced cancer screening to expert perspectives on the future of genomic testing.
Helio Genomics is built on nearly a decade of research in DNA methylation and AI-driven early cancer detection. This is where we share what we are learning — educational deep-dives, research updates, and candid conversations with the experts advancing the field.
Stories from the lab
Educational articles on early cancer detection, genomics, and the science behind HelioLiver.
Early cancer diagnosis and artificial intelligence are both rapidly evolving fields — and where they converge, they are changing how we identify the DNA signatures that predict cancer as early as stage 1.
How the largest prospective U.S. liquid-biopsy liver cancer trial showed HelioLiver detecting HCC earlier than ultrasound.
Read moreA look at how cell-free DNA methylation, protein biomarkers, and AI combine to read the earliest signals of cancer.
Read moreTracing the published research behind HelioLiver — from foundational methylation studies to pivotal clinical trials.
Read moreWhen liver cancer is found early, treatment options multiply and survival rates climb. Here is why timing matters so much.
Read moreAn overview of the trials and performance data that support HelioLiver as a guideline-aligned surveillance tool.
Read moreListen to our leadership share their latest insights on the oncology and diagnostic landscape.
Helio Genomics' CEO sits down with Nasdaq's Kristina Ayanian to discuss how the AI-driven healthcare company is on a mission to save lives by detecting cancer early from a simple blood draw.
Watch InterviewFeatured in Precision Medicine Online. Catherine Shaffer interviews Helio Genomics CEO Justin Chen Li on the company’s pipeline and U.S. launch plans.
Read InterviewHelio Genomics CEO Justin Chen Li is interviewed by the Orange County Business Journal about recent research on multimodal epigenetic sequencing analysis (MESA).
Read InterviewHelio Genomics' CEO discusses the company's roadmap for bringing AI-driven, blood-based early cancer detection to patients at scale across the United States.
Read InterviewSubscribe for new articles, interviews, and research milestones — or reach our team to learn more about HelioLiver and the science behind earlier detection.